Basis: (FMP quote price / unrounded diluted TTM EPS) / five-year diluted EPS CAGR in percent, from annual statements through the period end shown. Source: stored company filings and market data; unavailable inputs remain N/A.
The PEG ratio is N/A as of 2026-10-06T17:57:53.089Z.
Calculation as of: 2026-10-06T17:57:53.089Z.
Quote observation: 2026-10-06T17:54:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 954f90b5803147d7e77bb33cb230df589f2ac0b2215919e8afc4fbf9605c1a4a
PEG RATIO
N/A
Profound Medical Corp.
Market Cap
$223.48M
PEG Ratio
N/A
| NAME | MARKET CAP | PEG RATIO |
|---|---|---|
| Profound Medical Corp. (PROF) | $223.48M | N/A |
| Keros Therapeutics, Inc. (KROS)vs › | $223.45M | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $216.82M | N/A |
| Biodesix, Inc. (BDSX)vs › | $228.74M | N/A |
| Vogenx Inc. (VOGX)vs › | $229.03M | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $214.64M | N/A |
| Lyell Immunopharma, Inc. (LYEL)vs › | $214.41M | N/A |
| MacroGenics, Inc. (MGNX)vs › | $232.01M | N/A |
| Nautilus Biotechnolgy, Inc. (NAUT)vs › | $232.88M | N/A |
| Prelude Therapeutics Incorporated (PRLD)vs › | $211.79M | N/A |
PEG Ratio
N/A
P/E Ratio
N/A
PEG Ratio = P/E Ratio / 5-Year Diluted EPS CAGR (%)
The PEG ratio divides the price-to-earnings ratio by the company's five-year compound annual growth rate of diluted EPS, expressed in percent. A P/E of 20 and a five-year diluted EPS CAGR of 10% give a PEG of 2.0. The growth is reported, historical earnings growth from annual statements, not an analyst forecast. A PEG near 1 is often read as fairly priced for its growth; lower can mean cheaper relative to growth. The ratio is N/A when the P/E is unavailable or not positive, or when the five-year diluted EPS CAGR is unavailable or not positive. Each day of the history uses the CAGR that was known on that day.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
